Jane Street’s Design Therapeutics DSGN Stock Holding History

Jane Street’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.11M	Sell	103,902 -122,610	-54%	-$1.24M	﹤0.01%	6275
2025 Q4	$2.12M	Buy	226,512 +108,679	+92%	+$851K	﹤0.01%	4699
2025 Q3	$887K	Buy	117,833 +86,754	+279%	+$435K	﹤0.01%	6580
2025 Q2	$105K	Buy	31,079 +12,954	+71%	+$48.5K	﹤0.01%	8926
2025 Q1	$70K	Buy	+18,125	New	+$86.5K	﹤0.01%	8925
2024 Q4	–	Sell	-24,003	Closed	-$129K	–	9632
2024 Q3	$129K	Sell	24,003 -33,902	-59%	-$159K	﹤0.01%	8883
2024 Q2	$194K	Buy	+57,905	New	+$226K	﹤0.01%	8407
2024 Q1	–	Sell	-54,693	Closed	-$145K	–	9373
2023 Q4	$145K	Buy	54,693 +25,310	+86%	+$58K	﹤0.01%	8412
2023 Q3	$69.3K	Sell	29,383 -3,951	-12%	-$18.4K	﹤0.01%	8072
2023 Q2	$210K	Sell	33,334 -169,390	-84%	-$1.04M	﹤0.01%	7627
2023 Q1	$1.17M	Buy	+202,724	New	+$1.52M	﹤0.01%	4728
2022 Q3	–	Sell	-12,705	Closed	-$178K	–	9840
2022 Q2	$178K	Buy	+12,705	New	+$172K	﹤0.01%	8278

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street's DSGN Position: Q1 2026 in Review

Jane Street reduced its Design Therapeutics (DSGN) stake by 54% in Q1 2026, selling an estimated $1.24M and leaving 103,902 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #6275.

Jane Street first reported a position in DSGN in Q2 2022 and has held it in 12 quarters since. The position peaked at $2.12M in Q4 2025. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

Jane Street held 103,902 shares of Design Therapeutics worth $1.11M as of Q1 2026.
Jane Street sold 122,610 Design Therapeutics shares in Q1 2026, an estimated $1.24M.
Design Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #6275 holding.
Jane Street first reported a position in Design Therapeutics in Q2 2022 and has held it in 12 quarters since.
Jane Street's Design Therapeutics position peaked at $2.12M in Q4 2025.
125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.